Further characterization of the sensitivity or resistance to TRAIL in breast cancer cells is needed to identify a mechanistic basis for the selectivity seen in preclinical studies as this will likely lead to a more robust predictive biomarker. The gene discussed is TNFSF10; the disease is breast carcinoma.